What's new? Log in Free sign up

Cocrystal Pharma (COCP) News and press releases

Company Profile

News

From Benzinga Pro

Why eHealth Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Inpixon (NASDAQ: INPX) shares rose 41% to $2.20 in pre-market trading after gaining 6% on Tuesday. Inpixon, last month, secured a purchase order valued at over $1m for its RTLS products from a leading transportation and industrial equipment provider.

HC Wainwright & Co. Maintains Buy on Cocrystal Pharma, Lowers Price Target to $35

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cocrystal Pharma (NASDAQ:COCP) with a Buy and lowers the price target from $42 to $35.

Cocrystal Pharma Discusses Clinical Progress And Significance Of Its Novel Antiviral Therapeutics Pipeline With The Stock Day Podcast

The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal," "Cocrystal Pharma" or "the Company"), a clinical-stage biotechnology company discovering and developing

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 258 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

Tuesday's session saw 325 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Friday

OnFriday, 143 stocks hit new 52-week lows.

Cocrystal Pharma Reports Highly Favorable Safety And Tolerability Results From A Phase 1 Study With Its Oral Antiviral CC-42344 For The Treatment Of Pandemic And Seasonal Influenza A

Biotech, News, FDA, General

Cocrystal Pharma, Inc. (NASDAQ:COCP) announces highly favorable safety and tolerability results for its orally administered replication inhibitor CC-42344 in its Phase 1 study. CC-42344 is a

Cocrystal Pharma Highlights Progress with CC-42344; Affirms Plans To Report Topline Phase 1 Results In 2022, Initiate Phase 2a Influenza Human Challenge Trial In 2023

Biotech, News, Health Care, General

Cocrystal Pharma, Inc. (NASDAQ:COCP) announces that progress with CC-42344 for the treatment of pandemic and seasonal influenza A from its Phase 1 study was presented today at the World Antiviral Congress 2022

Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A

Biotech, News, Penny Stocks, Health Care, General

Cocrystal Pharma Announces Safety Data From The Phase 1 Study With Oral Antiviral CC-42344 For The Treatment Of Pandemic And Seasonal Influenza A

Biotech, News, FDA, General

Cocrystal Pharma, Inc. (NASDAQ:COCP) today announced that CC-42344 demonstrated a favorable safety profile in both the single-ascending dose and the multiple-ascending dose portions of the ongoing Phase 1

Cocrystal Pharma Q3 EPS $(0.70) Down From $(0.48) YoY

Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.70) per share. This is a 45.83 percent decrease over losses of $(0.48) per share from the same period last year.

HC Wainwright & Co. Maintains Buy on Cocrystal Pharma. Adjusts price $4 to $42

News, Analyst Ratings

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cocrystal Pharma (NASDAQ:COCP) with a Buy. Adjusts price $4 to $42

Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results.

Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results.

Cocrystal Pharma Has Been Granted European Patent Number EP3866778 Titled "Combinations Of Inhibitors Of Influenza Virus Replication"

Biotech, News, General

About this file - European Patent Register (epo.org) (2) PatentGrants on Twitter: "$COCP Cocrystal Pharma has been granted European patent number EP3866778 titled "COMBINATIONS OF INHIBITORS OF INFLUENZA VIRUS

Press releases

From Benzinga Pro

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - January 23, 2023) - The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal," "Cocrystal Pharma" or "the Company"), a clinical-stage biotechnology company

Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

BOTHELL, Wash., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) announces highly favorable safety and tolerability results for its orally administered replication inhibitor CC-42344 in its Phase

Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

Affirms plans to report topline Phase 1 results in 2022 and to initiate Phase 2a influenza human challenge trial in 2023 BOTHELL, Wash., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP)

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

BOTHELL, Wash., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) today announced that CC-42344 demonstrated a favorable safety profile in both the single-ascending dose and the multiple-ascending

Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza

BOTHELL, Wash., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) announces it has been granted European patent EP3866778 titled "Combinations Of Inhibitors of Influenza Virus Replication,"